Literature DB >> 20481648

Multiple peaking phenomena in pharmacokinetic disposition.

Neal M Davies1, Jody K Takemoto, Dion R Brocks, Jaime A Yáñez.   

Abstract

Multiple peaking in the blood fluid concentration-time curve is a phenomenon occasionally encountered in pharmacokinetics. When it occurs, it can create difficulties in the determination and interpretation of pharmacokinetic parameters. Multiple peaking can occur as a consequence of a number of different mechanisms. These include, in addition to others, factors related to the formulation, be it the drug chemical entity itself or other formulation-related factors such as the excipients incorporated into the product design. Another contributing factor that can work in concert with the formulation is the physiological makeup of the gastrointestinal tract itself. This includes the pH and components of bile such as bile salts and phospholipids, the secretion of which is regulated by hormonal and dietary factors. In some cases, biochemical differences in the regional areas of the gastrointestinal tract, such as regio-specificity in bile concentrations and/or transport proteins, could contribute to windows for absorption that result in multiple peaking of xenobiotics. One of the most common sources of multiple peaking is contributed by biliary secretion followed by intestinal reabsorption of a drug, a process for which the term 'enterohepatic recycling' has been coined. This cause of multiple peaking is associated with special consideration in the calculation and interpretation of the drug clearance and volume of distribution. In this review, each of these various causes of multiple peaking is discussed, with incorporation of relevant examples for illustrative purposes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20481648     DOI: 10.2165/11319320-000000000-00000

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  229 in total

1.  Bioavailability, disposition, and dose-response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes.

Authors:  Kenneth D R Setchell; Nadine Maynard Brown; Pankaj B Desai; Linda Zimmer-Nechimias; Brian Wolfe; Abhijeet S Jakate; Vivian Creutzinger; James E Heubi
Journal:  J Nutr       Date:  2003-04       Impact factor: 4.798

2.  Discontinuous oral absorption of cimetropium bromide, a new antispasmodic drug.

Authors:  B P Imbimbo; S Daniotti; A Vidi; D Foschi; F Saporiti; L Ferrante
Journal:  J Pharm Sci       Date:  1986-07       Impact factor: 3.534

3.  Pharmacokinetics of drugs subject to enterohepatic circulation.

Authors:  H S Chen; J F Gross
Journal:  J Pharm Sci       Date:  1979-06       Impact factor: 3.534

4.  Pharmacokinetic compartmental model with n sites of absorption along the gastrointestinal tract.

Authors:  Y Plusquellec; G Houin
Journal:  Arzneimittelforschung       Date:  1994-05

5.  Pharmacokinetics of methyldopa in man.

Authors:  K C Kwan; E L Foltz; G O Breault; J E Baer; J A Totaro
Journal:  J Pharmacol Exp Ther       Date:  1976-08       Impact factor: 4.030

6.  Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function.

Authors:  D R Guay; G R Matzke; H N Bockbrader; J Dancik
Journal:  Clin Pharm       Date:  1983 Mar-Apr

7.  Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.

Authors:  Serge Cremers; Rik Schoemaker; Eduard Scholten; Jan den Hartigh; Jacqueline König-Quartel; Eric van Kan; Leendert Paul; Johan de Fijter
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

8.  Comparative pharmacokinetics of fentanyl and alfentanil.

Authors:  S Bower; C J Hull
Journal:  Br J Anaesth       Date:  1982-08       Impact factor: 9.166

Review 9.  Bioavailability of phyto-oestrogens.

Authors:  Ian Rowland; Marian Faughnan; Leane Hoey; Kristiina Wähälä; Gary Williamson; Aedin Cassidy
Journal:  Br J Nutr       Date:  2003-06       Impact factor: 3.718

10.  Pharmacokinetics of pafenolol in the rat: a suitable model for studying absorption mechanisms of a drug exhibiting unusual absorption properties in man.

Authors:  H Lenneräs; C G Regårdh
Journal:  Biopharm Drug Dispos       Date:  1990-10       Impact factor: 1.627

View more
  34 in total

1.  Target-Mediated Drug Disposition Pharmacokinetic-Pharmacodynamic Model of Bosentan and Endothelin-1.

Authors:  Anke-Katrin Volz; Andreas Krause; Walter Emil Haefeli; Jasper Dingemanse; Thorsten Lehr
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

2.  Reply to Banda et al., "Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine".

Authors:  Stephen Walimbwa; Mohammed Lamorde; Catriona Waitt; Alieu Amara; Saye Khoo
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

3.  Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the characterization of atypical complex absorption kinetics.

Authors:  Lien Ngo; Hee-Doo Yoo; Phuong Tran; Hea-Young Cho; Yong-Bok Lee
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-03-18       Impact factor: 2.745

4.  Population pharmacokinetic model to analyze nevirapine multiple-peaks profile after a single oral dose.

Authors:  Manuel Ibarra; Marta Vázquez; Pietro Fagiolino
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-07-27       Impact factor: 2.745

5.  Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients.

Authors:  Nastja Lunar; Marie-Christine Etienne-Grimaldi; Pauline Macaire; Fabienne Thomas; Florence Dalenc; Jean-Marc Ferrero; Xavier Pivot; Gérard Milano; Bernard Royer; Antonin Schmitt
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-02       Impact factor: 3.333

6.  Development of an Enantioselective and Biomarker-Informed Translational Population Pharmacokinetic/Pharmacodynamic Model for Etodolac.

Authors:  Carolina de Miranda Silva; Adriana Rocha; Eduardo Tozatto; Lucienir Maria da Silva; Eduardo Antônio Donadi; Teresa Dalla Costa; Vera Lucia Lanchote; Stephan Schmidt; Jürgen B Bulitta
Journal:  AAPS J       Date:  2017-09-05       Impact factor: 4.009

7.  Design of biorelevant test setups for the prediction of diclofenac in vivo features after oral administration.

Authors:  Marie Guhmann; Markus Thommes; Frédéric Gerber; Norbert Pöllinger; Sandra Klein; Jörg Breitkreutz; Werner Weitschies
Journal:  Pharm Res       Date:  2013-03-30       Impact factor: 4.200

8.  Noscapine recirculates enterohepatically and induces self-clearance.

Authors:  Rao Mukkavilli; Sushma R Gundala; Chunhua Yang; Gajanan R Jadhav; Subrahmanyam Vangala; Michelle D Reid; Ritu Aneja
Journal:  Eur J Pharm Sci       Date:  2015-05-28       Impact factor: 4.384

9.  Respiratory arrest and oversedation in an adolescent given intramuscular clonazepam for rapid tranquillization.

Authors:  Jonathan Channing; Simon Hill; Marion Wetherill; Oliver White
Journal:  Ther Adv Psychopharmacol       Date:  2012-08

10.  Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer.

Authors:  Therese Ericsson; Antje Blank; Cornelia von Hagens; Michael Ashton; Angela Äbelö
Journal:  Eur J Clin Pharmacol       Date:  2014-09-25       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.